The Valley Desk

NCT02187302 · Interventional trial

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Overall registry status Completed

Phase 2

Conditions Metastatic Renal Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov